Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are associated with poor clinical outcomes. Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are observed in FLT3-ITD-positive patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691. Using biochemical assays, we determined that crenolanib, a novel TKI, demonstrates type I properties and is active against FLT3 containing ITD and/or D835- or F691-activating mutations. Potent activity was observed in FLT3-ITD-positive AML cell lines. Crenolanib delayed the outgrowth of MV4-11 cells in a xenograft mouse model, whereas in combination with the type II TKI sorafenib, a significant decrease in leukemic burden (P < .001) and prolonged survival (P < .01) was observed compared with either type I or II TKI alone. Crenolanib was active against Ba/F3 cells harboring FLT3-ITD and secondary KD mutations and sorafenib-resistant MOLM-13 cells containing FLT3-ITD/D835Y both in vitro and in vivo. In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations. These preclinical data demonstrate that crenolanib is effective against FLT3-ITD containing secondary KD mutations, suggesting that crenolanib may be a useful therapeutic agent for TKI-naive and drug-resistant FLT3-ITD-positive AML.

[1]  Judith A. Cohen,et al.  Investigator’s brochure , 2014 .

[2]  A. Reiter,et al.  Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V , 2013, Haematologica.

[3]  S. Shurtleff,et al.  Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia , 2013, Clinical Cancer Research.

[4]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[5]  S. Meshinchi,et al.  Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia , 2013, Pediatric blood & cancer.

[6]  Catherine C. Smith,et al.  Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. , 2013, Blood.

[7]  F. Ferrara,et al.  Acute myeloid leukaemia in adults , 2013, The Lancet.

[8]  M. Levis,et al.  Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations , 2012 .

[9]  M. Carroll,et al.  Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants , 2012 .

[10]  M. Konopleva,et al.  Combination of Crenolanib with Sorafenib Produces Synergistic Pro-Apoptotic Effects in FLT3-ITD-Inhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations , 2012 .

[11]  D. Johnston,et al.  Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. , 2012, Blood.

[12]  F. Giles,et al.  Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia , 2012, Leukemia.

[13]  M. Heinrich,et al.  Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2012, Clinical Cancer Research.

[14]  S. Lok,et al.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. , 2012, Blood.

[15]  A. Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[16]  P. Workman,et al.  Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns , 2012, Leukemia.

[17]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[18]  S. Knapper.  The clinical development of FLT3 inhibitors in acute myeloid leukemia , 2011, Expert opinion on investigational drugs.

[19]  D. Campana,et al.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. , 2011, Journal of the National Cancer Institute.

[20]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Lipka,et al.  FLT3 as a therapeutic target in AML: still challenging after all these years. , 2010, Blood.

[22]  Daniel K Treiber,et al.  Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. , 2010, Chemistry & biology.

[23]  P. Furet,et al.  Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. , 2010, Genes & cancer.

[24]  M. Sattler,et al.  Drug resistance in mutant FLT3-positive AML , 2010, Oncogene.

[25]  C. Antonescu,et al.  Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib , 2010, Molecular Cancer Research.

[26]  K. Pierce,et al.  Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Zarrinkar,et al.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.

[28]  Yan Zhang,et al.  KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients , 2009, Proceedings of the National Academy of Sciences.

[29]  B. Druker,et al.  Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. , 2006, Blood.

[30]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[31]  Y. Ravindranath.  Recent advances in pediatric acute lymphoblastic and myeloid leukemia , 2003, Current opinion in oncology.

[32]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[33]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[34]  M. Patnaik,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.